PDF icon Download PDF
Open Access
CC BY-NC-ND 4.0 · Asian J Neurosurg 2023; 18(03): 567-572
DOI: 10.1055/s-0043-1771372
Original Article

A Prospective Study of the Effect and Safety of Atorvastatin on the Recurrence of Chronic Subdural Hematoma after Burr Hole Surgery

Duangkamol Bumpetch
1   Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
2   Department of Surgery, Nan Hospital, Nan, Thailand
,
Bunpot Sitthinamsuwan 
1   Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
,
Sarun Nunta-aree
1   Division of Neurosurgery, Department of Surgery, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
› Author Affiliations
Funding This research project was supported by the Siriraj Research Fund, Grant number (IO) R016231044, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
› Further Information
Also available ateRef
  Permissions and Reprints
Preview

Abstract

Introduction Chronic subdural hematoma (CSDH) is a common neurosurgical condition. Recent studies showed efficacy of atorvastatin in reducing the requirement of surgical treatment. This study aimed to evaluate the efficacy and safety of atorvastatin in reducing the recurrence of CSDH after burr hole surgery.

Methods This prospective study included patients with CSDH who underwent burr hole surgery. Atorvastatin at 20 mg per day was administered to all patients for 4 weeks postoperatively. The major outcome was the recurrence rate of CSDH at 8 weeks following the operation.

Results Seventy-three patients who completed the 4-week course of atorvastatin were included. The mean age was 73.9 years. The most common cause of CSDH was falling. The mean hematoma volume was 106.3 mL. There was no adverse effect of atorvastatin in all of 73 patients. During the 8-week postoperative period, recurrent CSDH was found in 2 of 73 (2.7%) patients. In a comparison of the recurrence rate of CSDH between patients with use of atorvastatin from the present and previous studies (2.6–4.8%), and patients without use of atorvastatin from previous studies (9.8–19%), a marked reduction in recurrent CSDH after burr hole surgery was found in patients with use of atorvastatin.

Conclusion An administration of atorvastatin of 20 mg daily for 4 weeks following burr hole surgery is safe and may be helpful in reducing the recurrence rate of CSDH after burr hole surgery.

Keywords

atorvastatin - burr hole - chronic subdural hematoma - recurrence

Authors' Contributions

D.B. contributed to the development or design of methodology, project administration, software, investigation, data collection, formal analysis, visualization, original draft preparation, and approval of the final manuscript. B.S. contributed to the development or design of methodology, formal analysis, visualization, reviewing and editing of the manuscript, and approval of the final manuscript. S.N.-a. contributed to the conceptualization, supervision, reviewing and editing of the manuscript, corresponding author, and approval of the final manuscript.


Ethical Approval

This study was approved by the Ethics Committee of the Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand; Certificate of Approval (COA) number SI 355/2019. All the patients' data retained full confidentiality in compliance with the Declaration of Helsinki.




Publication History

Article published online:
31 August 2023

© 2023. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India